The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | The use of real-world evidence to guide CAR T-cell therapy for patients with LBCL
Sairah Ahmed, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the value of real-world evidence in guiding treatment decisions and patient selection for CAR T-cell therapy in large B-cell lymphoma (LBCL). Dr Ahmed highlights that real-world evidence helps bridge the gap between clinical trial data and real-world patient populations, demonstrating that patients with comorbidities who were not eligible for clinical trials can still achieve similar outcomes with CAR T-cell therapy. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So when we look at the clinical trial data for patients who receive CAR T-cell therapy for large cell lymphoma, those patients are not necessarily indicative of the patients that we treat in clinic. And the real-world evidence has demonstrated that up to 65% of patients would not have been eligible for clinical trials based on either comorbidity status and or other parameters...
So when we look at the clinical trial data for patients who receive CAR T-cell therapy for large cell lymphoma, those patients are not necessarily indicative of the patients that we treat in clinic. And the real-world evidence has demonstrated that up to 65% of patients would not have been eligible for clinical trials based on either comorbidity status and or other parameters. So the real-world evidence really helps us to understand the patients that are coming into clinic and how they will do with the therapy that we’re prescribing. And the interesting part is that efficacy-wise CAR T-cell therapy is the same in clinical trials as it is in the real-world evidence. Patients who have comorbidities such as renal dysfunction, cardiac dysfunction, and other types of cytopenias which may have precluded them from going on trial have similar overall response rate, complete response rates, progression-free survival, and overall survival. So I think it really helps to demonstrate that we can still treat these patients and hope for the same outcomes.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
